Foghorn Cash Ratio from 2010 to 2024

FHTX Stock  USD 7.72  0.14  1.78%   
Foghorn Therapeutics Cash Ratio yearly trend continues to be fairly stable with very little volatility. Cash Ratio will likely drop to 1.31 in 2024. During the period from 2010 to 2024, Foghorn Therapeutics Cash Ratio regression line of annual values had r-squared of  0.73 and arithmetic mean of  7.73. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
1.37476898
Current Value
1.31
Quarterly Volatility
4.94178209
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 11.1 M, Interest Income of 11.1 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 7.53, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Foghorn Therapeutics Correlation against competitors.
For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Foghorn Therapeutics over the last few years. It is Foghorn Therapeutics' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

Foghorn Cash Ratio Regression Statistics

Arithmetic Mean7.73
Geometric Mean5.35
Coefficient Of Variation63.89
Mean Deviation4.60
Median11.57
Standard Deviation4.94
Sample Variance24.42
Range10.5429
R-Value(0.85)
Mean Square Error7.10
R-Squared0.73
Significance0.00005
Slope(0.94)
Total Sum of Squares341.90

Foghorn Cash Ratio History

2024 1.31
2023 1.37
2022 1.03
2021 2.08
2020 4.92
2019 1.18

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Cash Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Ratio 1.37  1.31 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.